GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing Ready to Announce with Confidence?
Boca Raton, Florida--(Newsfile Corp. - April 28, 2026) - GridAI Technologies Corp. (NASDAQ: GRDX) (the "Company") today announced that On April 22, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the filing of periodic financial reports requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5250(c)(1), because the Company has not yet filed its 10-K for the period ended December 31, 2025.
The Company has 60 calendar days from April 22, 2026, or through June 22, 2026, to submit to Nasdaq a plan to regain compliance with Listing Rule 5250(c)(1). If Nasdaq accepts the Company's plan, Nasdaq may grant an extension of up to 180 calendar days from April 15, 2026, or through October 12, 2026, to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the right to appeal such decision to a Nasdaq hearings panel.
The delay in filing the Company's Annual Report on Form 10-K is due to the complexity in reviewing the accounting treatment and other information related to the Company's recent acquisition of Grid AI Corp. The Company intends to file its Annual Report on Form 10-K as soon as possible, and to submit to Nasdaq, within the requisite time period, a plan to regain compliance with Listing Rule 5250(c)(1). There can be no assurance that Nasdaq will accept the Company's plan or that the Company will be able to regain compliance with Listing Rule 5250(c)(1) or maintain compliance with any other Nasdaq requirement in the future.
About GridAI Technologies Corp.
GridAI Technologies Corp. (NASDAQ: GRDX), formerly known as Entero Therapeutics, Inc., is a diversified technology and life sciences company operating through two principal areas: (i) energy orchestration and grid optimization software solutions through our subsidiary Grid AI Corp. and (ii) legacy biopharmaceutical development activities centered on Adrulipase for the treatment of exocrine pancreatic insufficiency.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
For Investor Relations inquiries, please contact:
Jérôme Cliche
ONCORE Network LLC
Tel: +1 (646) 960-8760 Email: ir@oncorenetwork.com
Corporate Communications
IBNAustin,
Texas www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294446
Source: GridAI Technologies Corp.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for GridAI Technologies Corp. or all companies in the Technology, Biotechnology industry.
GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing
2026-04-28 5:20 PM EDT
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
2025-10-01 8:30 AM EDT
Entero Therapeutics, Inc. Announces Reverse Stock Split
2025-08-14 9:15 AM EDT
Mar 30, 2026
Eligible venture issuers in Canada can now move from quarterly to semi-annual reporting. As of March 19, 2026, the Canadian Securities Administrators (CSA) introduced the Semi-Annual Reporting (SAR) Pilot . Implemented through Coordinated Blanket Order 51-933, it allows certain issuers listed on the TSX Venture Exchange (TSXV) or the Canadian Securities Exchange (CSE) to optionally skip first and third quarter financial filings . This reduces overall reporting burdens and costs. It also...
Economy, Business and Finance
Biotechnology
Chemicals
Science and Technology
Technology
Biotechnology